T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
Trastuzumab deruxtecan (T-DXd) improved physical/role functioning and pain in HR+, HER2-low/-ultralow metastatic breast cancer patients compared to treatment of physician’s choice (TPC), with significant reductions in pain deterioration (22.0 months vs 6.3 months) and other symptoms, while maintaining global health/QOL over 31 weeks.
Related Clinical Trials
Highlighted Terms
Related News
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2-Low/Ultralow MBC
Trastuzumab deruxtecan (T-DXd) improved physical/role functioning and pain in HR+, HER2-low/-ultralow metastatic breast cancer patients compared to treatment of physician’s choice (TPC), with significant reductions in pain deterioration (22.0 months vs 6.3 months) and other symptoms, while maintaining global health/QOL over 31 weeks.